Sacubitril/Valsartan vs Standard Treatment for Preventing Atrial Fibrillation Recurrence After Catheter Ablation in Persistent Atrial Fibrillation Patients With Without Hypertension

A phase 4 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 472 participants.

Also called NCT07910058

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; single masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 472 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT07910058
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Not reported
Registry status
  • Not yet recruiting (from the registry)

Technical summary

Registry record NCT07910058. Randomized; single masking; primary purpose treatment. Start 2026-10-31 (anticipated); primary completion 2029-03-31 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Sacubitril/Valsartan vs Standard Treatment for Preventing Atrial Fibrillation Recurrence After Catheter Ablation in Persistent Atrial Fibrillation Patients With Without Hypertension
Acronym
SUPERIOR 2
Condition
Atrial Fibrillation (Persistent)
Condition
Non-hypertension
Condition
Angiotensin Receptor/Neprilysin Inhibitor
Intervention (Drug)
Sacubitril/Valsartan
Intervention (Other)
Standard Care
Lead sponsor
Ruijin Hospital (class: other)

Record details

Record id
cardio:ct-nct07910058
Content hash
1056ef74fed73281de7f0b8e0bb07fb44a47366e4645f6aed2af69b51dbc6ffb